Author: Cyril Barabaltchouk

From 50 football pitches worth of sunflowers, to the destruction of Marinka town in Ukraine – here are the images of the day chosen by the Sky News picture editors.Read More

Read More

STORY: Trump in a social media post called Tan, who was hired in March to turn around the struggling chipmaker, “highly conflicted” due to the Intel CEO’s ties to Chinese firms.Coons said that for Trump to say there is a conflict of interest “feels a little bit like the pot calling the kettle black.””There’s conflict all over the place,” Coons added. “We just have to be real about that.”A leadership change could pile pressure on Intel, which is a pillar of U.S. efforts to boost domestic chipmaking, after the chipmaker secured $8 billion in government subsidies to build new factories…

Read More

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in Skye’s CBeyondTM Phase 2a obesity trial extension study initiated Independent Data Safety Monitoring Committee completed fourth unblinded review with no concerns raised; CBeyondTM study continues per protocolNew preclinical study highlights superior weight rebound profile of nimacimab compared to incretin therapy.Preclinical data shows dosing nimacimab in combination withRead More

Read More

– May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) – – CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 study initiation in CRC anticipated 1H 2026 – – Combination dose escalation initiated of CX-801 masked interferon alpha-2b with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma – – Completed $100 million underwritten offering of commoRead More

Read More